Longboard Pharmaceuticals, Inc. Stock

Equities

LBPH

US54300N1037

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-05-17 pm EDT 5-day change 1st Jan Change
20.69 USD +0.88% Intraday chart for Longboard Pharmaceuticals, Inc. +2.83% +243.12%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 2.14M Sales 2025 * - Capitalization 804M
Net income 2024 * -66M Net income 2025 * -93M EV / Sales 2024 * 251 x
Net cash position 2024 * 267M Net cash position 2025 * 320M EV / Sales 2025 * -
P/E ratio 2024 *
-11.1 x
P/E ratio 2025 *
-9.06 x
Employees 50
Yield 2024 *
-
Yield 2025 *
-
Free-Float 85.5%
More Fundamentals * Assessed data
Dynamic Chart
Wedbush Adjusts Longboard Pharmaceuticals' PT to $34 From $32, Keeps Outperform Rating MT
Longboard Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Baird Starts Longboard Pharmaceuticals With Outperform Rating, $36 Price Target MT
Longboard Pharmaceuticals, Inc. announced that it has received $59.85 million in funding CI
Longboard Pharmaceuticals, Inc.(NasdaqGM:LBPH) added to S&P Pharmaceuticals Select Industry Index CI
Longboard Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Cantor Fitzgerald Raises Price Target on Longboard Pharmaceuticals to $60 From $55, Maintains Overweight Rating MT
B. Riley Raises Price Target on Longboard Pharmaceuticals to $30 From $13, Maintains Buy Rating MT
Longboard Pharmaceuticals Closes $242 Million Public Offering MT
HC Wainwright Adjusts Price Target on Longboard Pharmaceuticals to $60 From $25, Keeps Buy Rating MT
Wedbush Raises Longboard Pharmaceuticals' PT to $32 From $22, Says Offering Removes Near-Term Cash Runway Overhang, Provides Resources to Advance Bexicaserin; Keeps Outperform Rating MT
Longboard Pharmaceuticals Prices $210 Million Stock Offering MT
Longboard Pharmaceuticals Launching Share Offering MT
Sector Update: Health Care Stocks Gain Late Afternoon MT
Longboard Pharmaceuticals Shares Surge After Positive Topline Results for Seizures Treatment MT
More news

Latest transcript on Longboard Pharmaceuticals, Inc.

1 day+0.88%
1 week+2.83%
Current month-2.86%
1 month+14.88%
3 months-2.73%
6 months+377.83%
Current year+243.12%
More quotes
1 week
19.75
Extreme 19.75
21.41
1 month
17.50
Extreme 17.5
23.96
Current year
16.20
Extreme 16.2
28.15
1 year
3.60
Extreme 3.6
28.15
3 years
2.70
Extreme 2.7
28.15
5 years
2.70
Extreme 2.7
28.15
10 years
2.70
Extreme 2.7
28.15
More quotes
Managers TitleAgeSince
Chief Executive Officer 47 20-01-02
Director of Finance/CFO 50 20-12-31
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Chairman 65 20-11-30
Director/Board Member 67 20-11-30
Director/Board Member 56 20-01-31
More insiders
Date Price Change Volume
24-05-17 20.69 +0.88% 193,757
24-05-16 20.51 -2.98% 240,924
24-05-15 21.14 +3.88% 188,049
24-05-14 20.35 +2.11% 113,364
24-05-13 19.93 -0.94% 151,230

Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT

More quotes
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for neurological diseases. The Company is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). It is focused on developing various product candidates in its pipeline, which includes bexicaserin (LP352) and LP659. The Company plans to advance bexicaserin (LP352), an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor subtypes, into a global Phase 3 program. It is also evaluating LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of rare neuroinflammatory conditions. The Company is conducting a Phase 1 single-ascending dose (SAD) clinical trial for LP659 in healthy volunteers.
Calendar
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
20.69 USD
Average target price
42 USD
Spread / Average Target
+103.00%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW